Subtopic Deep Dive
Reverse Transcriptase Inhibitor Resistance
Research Guide
What is Reverse Transcriptase Inhibitor Resistance?
Reverse Transcriptase Inhibitor Resistance refers to the molecular mechanisms by which HIV-1 develops resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), primarily through mutations like M184V in the reverse transcriptase enzyme.
Resistance arises from point mutations in the HIV-1 RT gene that alter drug binding or enzyme function, reducing inhibitor efficacy. Key studies document NRTI combinations like zidovudine and lamivudine with indinavir slowing disease progression despite emerging resistance (Hammer et al., 1997, 2666 citations). Structural insights from RT-DNA crystal structures reveal binding sites targeted by mutations (Jacobo-Molina et al., 1993, 1105 citations). Over 10,000 papers address HIV RT inhibitors and resistance mechanisms.
Why It Matters
Resistance to RT inhibitors like zidovudine and lamivudine undermines first-line HIV therapies, necessitating resistance monitoring via genotyping to guide regimen switches (Gazzard, 2008). Hammer et al. (1997) showed triple therapy delays progression in advanced patients but highlighted resistance emergence. Arts and Hazuda (2012) emphasize understanding RT mutations for designing next-generation inhibitors. Triant et al. (2007) link NRTI use to cardiovascular risks, informing safer treatment strategies. Guidelines integrate resistance data for personalized antiretroviral therapy (Aberg et al., 2009).
Key Research Challenges
Detecting Low-Frequency Mutations
Next-generation sequencing is needed to identify minor resistant variants below Sanger detection limits. Standard genotyping misses subpopulations driving resistance (Sáez-Cirión et al., 2013). Phenotypic assays quantify fitness costs of mutations like M184V.
Understanding Mutation Fitness
Mutations confer drug resistance but often impair RT replication efficiency. Jacobo-Molina et al. (1993) RT structure shows how M184V distorts nucleotide binding. Balancing resistance and viral fitness challenges inhibitor design (Arts and Hazuda, 2012).
Cross-Resistance Prediction
Multiple RT mutations cause broad NRTI/NNRTI cross-resistance, complicating salvage therapy. Hammer et al. (1997) trial data reveal sequential NRTI failure patterns. Guidelines recommend resistance testing before regimen changes (Gazzard, 2008).
Essential Papers
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
· 1998 · Annals of Internal Medicine · 5.2K citations
Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected PersonsJune 15, 1998Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults...
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Scott M. Hammer, Kathleen Squires, Michael D. Hughes et al. · 1997 · New England Journal of Medicine · 2.7K citations
Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer pe...
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
Virginia A. Triant, Hang Lee, Colleen Hadigan et al. · 2007 · The Journal of Clinical Endocrinology & Metabolism · 1.6K citations
Abstract Context: Metabolic changes and smoking are common among HIV patients and may confer increased cardiovascular risk. Objective: The aim of the study was to determine acute myocardial infarct...
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.
Alfredo Jacobo‐Molina, Jianping Ding, Raymond G. Nanni et al. · 1993 · Proceedings of the National Academy of Sciences · 1.1K citations
The crystal structure of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) heterodimer (p66/p51), a 19-base/18-base double-stranded DNA template-primer, and ...
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
B G Gazzard, on behalf of the BHIVA Treatment Guidelines Writing Group · 2008 · HIV Medicine · 1.1K citations
Table of contents 1.0 Introduction 2.0 Methodology 2.1 Basing recommendations on evidence 2.2 Implications for research 2.3 Use of surrogate marker data 2.4 Issues concerning design and analysis of...
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
Asier Sáez‐Cirión, Charline Bacchus, Laurent Hocqueloux et al. · 2013 · PLoS Pathogens · 980 citations
Combination antiretroviral therapy (cART) reduces HIV-associated morbidities and mortalities but cannot cure the infection. Given the difficulty of eradicating HIV-1, a functional cure for HIV-infe...
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
Caroline Sabin, Signe Westring Worm, Rainer Weber et al. · 2008 · The Lancet · 911 citations
Reading Guide
Foundational Papers
Start with Jacobo-Molina et al. (1993) for RT crystal structure showing DNA binding pocket targeted by mutations, then Hammer et al. (1997) for clinical evidence of NRTI resistance in triple therapy trials.
Recent Advances
Study Arts and Hazuda (2012) for comprehensive RT inhibitor mechanisms review and Aberg et al. (2009) guidelines incorporating resistance testing protocols.
Core Methods
Core techniques include Sanger/next-gen sequencing for mutations, recombinant RT phenotypic assays for drug susceptibility, and X-ray crystallography for inhibitor-RT complexes (Jacobo-Molina et al., 1993).
How PapersFlow Helps You Research Reverse Transcriptase Inhibitor Resistance
Discover & Search
Research Agent uses searchPapers('M184V mutation resistance mechanisms') to retrieve 5,240 papers, then citationGraph on Jacobo-Molina et al. (1993) reveals 1,105 citing works on RT structures, and findSimilarPapers expands to phenotypic assays.
Analyze & Verify
Analysis Agent applies readPaperContent to Hammer et al. (1997) for resistance emergence data in triple therapy, verifyResponse with CoVe cross-checks mutation frequencies against Arts and Hazuda (2012), and runPythonAnalysis plots CD4 decline curves with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in NNRTI cross-resistance literature, flags contradictions between Gazzard (2008) guidelines and trial data, then Writing Agent uses latexEditText for mutation tables, latexSyncCitations for 50+ references, and latexCompile for a review manuscript.
Use Cases
"Analyze M184V mutation fitness costs from RT structural data"
Research Agent → searchPapers('M184V RT structure') → Analysis Agent → readPaperContent(Jacobo-Molina 1993) → runPythonAnalysis (NumPy modeling of binding energies) → matplotlib plot of fitness curves.
"Draft guidelines section on NRTI resistance monitoring"
Synthesis Agent → gap detection in Gazzard (2008) → Writing Agent → latexEditText('resistance testing protocols') → latexSyncCitations(Hammer 1997, Aberg 2009) → latexCompile → PDF with formatted tables.
"Find code for HIV RT mutation simulators"
Research Agent → searchPapers('HIV RT resistance simulation') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for mutation frequency modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ RT inhibitor resistance papers, chaining searchPapers → citationGraph → GRADE grading, producing structured report on M184V pathways. DeepScan applies 7-step analysis to Hammer et al. (1997) with CoVe verification at each checkpoint for trial resistance data accuracy. Theorizer generates hypotheses on novel inhibitor binding from Jacobo-Molina et al. (1993) structures.
Frequently Asked Questions
What defines Reverse Transcriptase Inhibitor Resistance?
HIV-1 mutations in the RT gene, like M184V, reduce NRTI/NNRTI binding affinity, enabling viral replication under drug pressure (Arts and Hazuda, 2012).
What are key methods for studying RT inhibitor resistance?
Genotypic sequencing detects mutations, phenotypic assays measure inhibitor IC50, and RT crystal structures reveal binding changes (Jacobo-Molina et al., 1993).
What are landmark papers on this topic?
Hammer et al. (1997, 2666 citations) showed NRTI triple therapy efficacy despite resistance; Jacobo-Molina et al. (1993, 1105 citations) provided RT-DNA structure.
What open problems remain in RT inhibitor resistance?
Predicting multi-mutation interactions and designing inhibitors overcoming M184V+K65R combinations; linking resistance to long-term controllers (Sáez-Cirión et al., 2013).
Research HIV/AIDS drug development and treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Reverse Transcriptase Inhibitor Resistance with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers